China: SGS to undertake extractables and leachables (E&L) testing at its Shanghai laboratory

GENEVA, 16-Jun-2017 — /EuropaWire/ — SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, today announced that it has significantly increased its capabilities to undertake extractables and leachables (E&L) testing at its Shanghai, China, laboratory.

Its investment includes the installation of multiple analytical instruments, including an isothermal static headspace gas chromatograph with flame ionization detector (HS-GC/MS-FID), two liquid chromatography–mass spectrometers (LC-MS) and one system. A liquid chromatography with time of flight mass spectrometer (LC-TOF-MS) has also been acquired, along with two inductively coupled plasma mass spectrometers (ICP-MS) and one inductively coupled plasma optical emission spectrometer (ICP-OES).

All instruments have undergone installation and validation and are fully 21 CFR part 11 compliant to ensure integrity of information for regulatory submissions.

In June 2016, SGS announced that it had expanded the laboratory in Shanghai and invested in instruments to undertake comprehensive drug compatibility study testing at the facility and to evaluate E&L contamination. This additional investment allows SGS to increase its capacity to handle E&L projects for applications including container testing, medical device evaluation and testing equipment used in pharmaceutical production.

“Extractables and leachables testing continues to be a much sought after service by the pharmaceutical industry, and SGS is renowned around the world for its expertise and experience in this area,” commented Andy Yi, General Manager, SGS Life Sciences, China. “This continued investment in the facilities in Shanghai doubles our capacity in the E&L field, and is in response to the rapid increase in demand from our clients, for whom regulatory compliance is paramount and who trust SGS to overcome analytical challenges effectively and efficiently.”

The investment in Shanghai is the latest undertaken by SGS in E&L testing capabilities, which has also seen the opening of a new global Center of Excellence for Extractable Studies and Impurities Profiling in Wiesbaden, Germany, and the expansion of services offered at its Fairfield, NJ, laboratory.

With 21 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.

For furhter information, please contact:

McKenzie Landgraf
Life Sciences – Marketing Manager
Agriculture, Food and Life
t: +1 301 556 0863
www.sgs.com/lifescience

Richard Kerns
President
NEPR
t: +44 (0)161 728 5880

About SGS
SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognised as the global benchmark for quality and integrity. With more than 90,000 employees, SGS operates a network of over 2,000 offices and laboratories around the world.

SOURCE: SGS SA